Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.
NCT ID: NCT01012375
Last Updated: 2011-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
135 participants
INTERVENTIONAL
2009-11-30
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00190775
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes
NCT00510276
Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)
NCT00190736
Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00191945
A Functional Outcomes Study With Atomoxetine-Hydrochloride and Placebo in Adults With Attention-Deficit/Hyperactivity Disorder
NCT00190931
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
AZD1446 tid
AZD1446
10 mg capsule, oral dose
2
AZD1446 tid
AZD1446
80 mg capsule, oral dose
3
AZD1446 qd
AZD1446
80 mg capsule, oral dose
4
Matching placebo capsule
Placebo
Matching capsule, oral dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD1446
10 mg capsule, oral dose
AZD1446
80 mg capsule, oral dose
AZD1446
80 mg capsule, oral dose
Placebo
Matching capsule, oral dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient understands and is willing to comply with all study requirements
* Adults between the ages of 18-65 inclusive
Exclusion Criteria
* Previous randomization into this study
* Women with a positive pregnancy test
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul A Newhouse, MD
Role: PRINCIPAL_INVESTIGATOR
Clinical Science Research Unit, Department of Psychiatry, University of Vermont,1 South Prospect Street, Burlington, VT 05401
Bjorn Paulsson, MD
Role: STUDY_DIRECTOR
AstraZeneca Pharmaceuticals, Kvarnbergagatan 12S-151 85, Sodertalje, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Los Alamitos, California, United States
Research Site
Fort Myers, Florida, United States
Research Site
New York, New York, United States
Research Site
Austin, Texas, United States
Research Site
Burlington, Vermont, United States
Research Site
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1950C00007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.